Information Provided By:
Fly News Breaks for January 17, 2020
MYOK
Jan 17, 2020 | 06:47 EDT
Wells Fargo analyst Jim Birchenough raised his price target for MyoKardia to $96 from $82 following an investor meeting in San Francisco, saying he came away with continued confidence in prospects for positive EXPLORER data, a clear path forward in noHCM and other HFpEF indications and on incremental value on dilated cardiomyopathy subpopulations for danicamtiv. The analyst made no change to his Overweight rating.
News For MYOK From the Last 2 Days
There are no results for your query MYOK
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.